Advice
Following a full resubmission.
Solifenacin succinate (Vesicare?) is accepted for use within NHS Scotland for the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.
Solifenacin is effective in reducing symptoms associated with overactive bladder, including frequency, urgency and incontinence. It is associated with adverse events typical of antimuscarinic agents used in this condition.
There are cheaper antimuscarinics available that would normally be used as first-line agents.
Download detailed advice51KB (PDF)
Medicine details
- Medicine name:
- Solifenacin (Vesicare®)
- SMC ID:
- 129/04
- Indication:
- Urge incontinence
- Pharmaceutical company
- Yamanouchi Pharma Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 07 November 2005